Marshall Wace’s CASI Pharmaceuticals CASI Stock Holding History

Marshall Wace’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30,051	Closed	-$241K	–	3398
2021 Q4	$241K	Sell	30,051 -65,153	-68%	-$649K	﹤0.01%	3100
2021 Q3	$1.13M	Buy	95,204 +72,833	+326%	+$985K	﹤0.01%	1939
2021 Q2	$347K	Buy	+22,371	New	+$376K	﹤0.01%	2277
2019 Q4	–	Sell	-3,116	Closed	-$104K	–	1723
2019 Q3	$104K	Buy	+3,116	New	+$100K	﹤0.01%	1393
2019 Q2	–	Sell	-1,525	Closed	-$44K	–	1390
2019 Q1	$44K	Buy	+1,525	New	+$53.1K	﹤0.01%	1549

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's CASI Position: Q1 2022 in Review

Marshall Wace sold out of CASI Pharmaceuticals (CASI) in Q1 2022, closing a stake of 30,051 shares — an estimated $241K sold.

Marshall Wace first reported a position in CASI in Q1 2019 and held it in 5 quarters. The position peaked at $1.13M in Q3 2021. 44 funds tracked by Wall St. Rank hold CASI as of Q1 2022.

Marshall Wace reported no remaining CASI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 30,051 CASI Pharmaceuticals shares in Q1 2022, an estimated $241K.
Marshall Wace first reported a position in CASI Pharmaceuticals in Q1 2019 and held it in 5 quarters.
Marshall Wace's CASI Pharmaceuticals position peaked at $1.13M in Q3 2021.
44 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.